|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.06 HKD | -1.17% |
|
-2.67% | +82.57% |
| Capitalization | 120B 132B 17.01B 14.45B 13.52B 12.67B 23.38B 1,547B 25.63B 158B 60.92B 727B 63.81B 62.48B 2,634B | P/E ratio 2025 * |
26.9x | P/E ratio 2026 * | 23.8x |
|---|---|---|---|---|---|
| Enterprise value | 114B 126B 16.14B 13.71B 12.82B 12.02B 22.18B 1,467B 24.31B 150B 57.79B 689B 60.54B 59.28B 2,499B | EV / Sales 2025 * |
5.28x | EV / Sales 2026 * | 4.49x |
| Free-Float |
86.37% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: WuXi Biologics (Cayman) Inc.
| 1 day | -1.17% | ||
| 1 week | -2.67% | ||
| Current month | +2.89% | ||
| 1 month | -3.78% | ||
| 3 months | -17.46% | ||
| 6 months | +14.50% | ||
| Current year | +82.57% |
| 1 week | 31.52 |  | 34.56 |
| 1 month | 30.3 | | 34.56 |
| Current year | 15.62 | | 42.6 |
| 1 year | 15.62 | | 42.6 |
| 3 years | 10.14 | | 77.4 |
| 5 years | 10.14 | | 148 |
| 10 years | 8.33 | | 148 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zhi Sheng Chen
CEO | Chief Executive Officer | 53 | 2015-12-31 |
Ming Tu
DFI | Director of Finance/CFO | 55 | 2021-08-22 |
Xuejun Gu
CTO | Chief Tech/Sci/R&D Officer | 54 | 2024-03-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Ge Li
CHM | Chairman | 57 | 2014-01-31 |
Zhi Sheng Chen
BRD | Director/Board Member | 53 | 2014-01-31 |
Yan Ling Cao
BRD | Director/Board Member | 41 | 2016-04-30 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 9.62% | 0 M€ | -19.71% | - |
| 4.23% | 0 M€ | -3.45% | - |
| 2.99% | 1 M€ | +14.13% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.17% | -2.67% | +80.11% | -34.10% | 17.21B | |
| +0.41% | -7.27% | +25.10% | +95.48% | 52.08B | |
| +1.90% | +3.35% | +173.43% | +950.63% | 42B | |
| -2.29% | -2.65% | +57.73% | +13.89% | 38.48B | |
| -1.68% | -3.78% | -19.25% | -47.37% | 22.56B | |
| -1.32% | -3.38% | +38.10% | -36.86% | 19.52B | |
| +0.60% | -6.03% | +83.66% | +187.22% | 13.75B | |
| -0.86% | +1.23% | -7.76% | +377.29% | 13.4B | |
| +0.45% | -9.29% | +115.57% | - | 12.06B | |
| -1.07% | +0.12% | +78.32% | +769.23% | 12.73B | |
| Average | -0.43% | -4.29% | +62.50% | +252.82% | 24.38B | |
| Weighted average by Cap. | -0.22% | -4.12% | +65.38% | +261.00% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 21.52B 23.78B 3.06B 2.6B 2.43B 2.28B 4.2B 278B 4.6B 28.37B 10.94B 131B 11.46B 11.23B 473B | 24.91B 27.52B 3.54B 3B 2.81B 2.63B 4.86B 322B 5.33B 32.83B 12.67B 151B 13.27B 12.99B 548B |
| Net income | 4.45B 4.92B 632M 537M 502M 471M 869M 57.48B 952M 5.87B 2.26B 27B 2.37B 2.32B 97.88B | 5.03B 5.56B 714M 607M 567M 532M 982M 64.92B 1.08B 6.63B 2.56B 30.5B 2.68B 2.62B 111B |
| Net Debt | -6.15B -6.79B -873M -741M -694M -650M -1.2B -79.36B -1.32B -8.1B -3.13B -37.29B -3.27B -3.21B -135B | -8.01B -8.85B -1.14B -966M -904M -847M -1.56B -103B -1.71B -10.56B -4.07B -48.59B -4.27B -4.18B -176B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-16 | 32.06 $ | -1.17% | 24,963,757 |
| 25-12-15 | 32.44 $ | -3.11% | 27,571,370 |
| 25-12-12 | 33.48 $ | 0.00% | 24,601,320 |
| 25-12-11 | 33.48 $ | -0.30% | 23,644,510 |
| 25-12-10 | 33.58 $ | +0.06% | 26,432,970 |
Delayed Quote Hong Kong S.E., December 16, 2025 at 03:08 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 2269 Stock
Select your edition
All financial news and data tailored to specific country editions
